635 related articles for article (PubMed ID: 26433848)
1. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
Quaglino P; Fierro MT; Rossotto GL; Savoia P; Bernengo MG
Br J Dermatol; 2004 Feb; 150(2):327-36. PubMed ID: 14996105
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
4. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
Stevens SR; Baron ED; Masten S; Cooper KD
Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
6. Extracorporeal photopheresis for the treatment of early-stage mycosis fungoides.
Lewis DJ; Duvic M
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28338261
[TBL] [Abstract][Full Text] [Related]
7. A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides.
Child FJ; Mitchell TJ; Whittaker SJ; Scarisbrick JJ; Seed PT; Russell-Jones R
Clin Exp Dermatol; 2004 May; 29(3):231-6. PubMed ID: 15115499
[TBL] [Abstract][Full Text] [Related]
8. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
[TBL] [Abstract][Full Text] [Related]
9. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.
Quaglino P; Knobler R; Fierro MT; Savoia P; Marra E; Fava P; Bernengo MG
Int J Dermatol; 2013 Nov; 52(11):1308-18. PubMed ID: 23786842
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
[TBL] [Abstract][Full Text] [Related]
11. What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?
Akilov OE
Cells; 2023 Sep; 12(18):. PubMed ID: 37759543
[TBL] [Abstract][Full Text] [Related]
12. State of the art therapy of mycosis fungoides and Sézary syndrome.
Kemme DJ; Bunn PA
Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
[TBL] [Abstract][Full Text] [Related]
13. The treatment of cutaneous T-cell lymphoma with photopheresis.
Zic JA
Dermatol Ther; 2003; 16(4):337-46. PubMed ID: 14686977
[TBL] [Abstract][Full Text] [Related]
14. Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single-centre experience.
Atzmony L; Amitay-Laish I; Gurion R; Shahal-Zimra Y; Hodak E
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2382-9. PubMed ID: 26299651
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.
Tsirigotis P; Pappa V; Papageorgiou S; Kapsimali V; Giannopoulou V; Kaitsa I; Girkas K; Papageorgiou E; Stavrianeas N; Economopoulos T; Dervenoulas J
Br J Dermatol; 2007 Jun; 156(6):1379-81. PubMed ID: 17459033
[No Abstract] [Full Text] [Related]
16. Photochemotherapy for mycosis fungoides: long-term followup study.
Roenigk HH
Cancer Treat Rep; 1979 Apr; 63(4):669-73. PubMed ID: 445519
[TBL] [Abstract][Full Text] [Related]
17. Photopheresis therapy for cutaneous T-cell lymphoma.
Duvic M; Hester JP; Lemak NA
J Am Acad Dermatol; 1996 Oct; 35(4):573-9. PubMed ID: 8859287
[TBL] [Abstract][Full Text] [Related]
18. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy.
Wilson LD; Licata AL; Braverman IM; Edelson RL; Heald PW; Feldman AM; Kacinski BM
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):987-95. PubMed ID: 7607973
[TBL] [Abstract][Full Text] [Related]
19. Mogamulizumab combined with extracorporeal photopheresis for the treatment of refractory mycosis fungoides and Sézary syndrome. Report of seven cases.
Rubio-Muniz CA; Sánchez-Velázquez A; Arroyo-Andrés J; Agud-de Dios M; Tarín-Vicente EJ; Falkenhain-López D; Ortiz-Romero PL
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e102-e105. PubMed ID: 37611255
[No Abstract] [Full Text] [Related]
20. Photopheresis in the treatment of cutaneous T-cell lymphoma: current status.
Zic JA
Curr Opin Oncol; 2012 Jan; 24 Suppl 1():S1-10. PubMed ID: 22157241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]